4.6 Review

HES1 in immunity and cancer

期刊

CYTOKINE & GROWTH FACTOR REVIEWS
卷 30, 期 -, 页码 113-117

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2016.03.010

关键词

HES1; NOTCH; Cancer; Immunity; Cytokine; Therapy

资金

  1. Medical Research Council [MR/J006742/1] Funding Source: Medline
  2. Medical Research Council [MR/J006742/1] Funding Source: researchfish

向作者/读者索取更多资源

Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix -loop -helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics. (C) 2016 Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据